Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink; Sigbjørn Berentsen; Jorge J. Castillo; Steven P. Treon; Marjan Cruijsen; Bruno Fattizzo; Ramona Cassin; Despina Fotiou; Efstathios Kastritis; Masja De Haas; Liesbeth E.M. Oosten; Henrik Frederiksen; Andrea Patriarca; Shirley D'Sa; Josephine M.I. Vos

doi:10.1182/blood.2021012039

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink^*, Sigbjørn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja De Haas, Liesbeth E.M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D'Sa, Josephine M.I. Vos

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Hæmatologi (Odense)

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	138
Udgave nummer	20
Sider (fra-til)	2002-2005
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood.2021012039
Status	Udgivet - 18. nov. 2021

Bibliografisk note

Funding Information:
Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.

Dokumenter og links

10.1182/blood.2021012039

Citationsformater

Jalink, M., Berentsen, S., Castillo, J. J., Treon, S. P., Cruijsen, M., Fattizzo, B., Cassin, R., Fotiou, D., Kastritis, E., De Haas, M., Oosten, L. E. M., Frederiksen, H., Patriarca, A., D'Sa, S., & Vos, J. M. I. (2021). Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood, 138(20), 2002-2005. https://doi.org/10.1182/blood.2021012039

@article{2e0590e5b701478797a9d9a89dfd4b52,

title = "Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome",

author = "Marit Jalink and Sigbj{\o}rn Berentsen and Castillo, {Jorge J.} and Treon, {Steven P.} and Marjan Cruijsen and Bruno Fattizzo and Ramona Cassin and Despina Fotiou and Efstathios Kastritis and {De Haas}, Masja and Oosten, {Liesbeth E.M.} and Henrik Frederiksen and Andrea Patriarca and Shirley D'Sa and Vos, {Josephine M.I.}",

note = "Funding Information: Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.",

year = "2021",

month = nov,

day = "18",

doi = "10.1182/blood.2021012039",

language = "English",

volume = "138",

pages = "2002--2005",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "20",

}

Jalink, M, Berentsen, S, Castillo, JJ, Treon, SP, Cruijsen, M, Fattizzo, B, Cassin, R, Fotiou, D, Kastritis, E, De Haas, M, Oosten, LEM, Frederiksen, H, Patriarca, A, D'Sa, S & Vos, JMI 2021, 'Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome', Blood, bind 138, nr. 20, s. 2002-2005. https://doi.org/10.1182/blood.2021012039

TY - JOUR

T1 - Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

AU - Jalink, Marit

AU - Berentsen, Sigbjørn

AU - Castillo, Jorge J.

AU - Treon, Steven P.

AU - Cruijsen, Marjan

AU - Fattizzo, Bruno

AU - Cassin, Ramona

AU - Fotiou, Despina

AU - Kastritis, Efstathios

AU - De Haas, Masja

AU - Oosten, Liesbeth E.M.

AU - Frederiksen, Henrik

AU - Patriarca, Andrea

AU - D'Sa, Shirley

AU - Vos, Josephine M.I.

N1 - Funding Information: Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.

PY - 2021/11/18

Y1 - 2021/11/18

U2 - 10.1182/blood.2021012039

DO - 10.1182/blood.2021012039

M3 - Comment/debate

C2 - 34293088

AN - SCOPUS:85116866947

SN - 0006-4971

VL - 138

SP - 2002

EP - 2005

JO - Blood

JF - Blood

IS - 20

ER -